Results 161 to 170 of about 1,615,435 (305)
A ROS‐responsive biomimetic nanoparticle platform co‐delivers DIDS and Mdivi‐1 to protect mitochondria and promote neural repair after intracerebral hemorrhage. By targeting LPAR1/VDAC1‐related mitochondrial dysfunction, the nanotherapy reduces oxidative injury, neuronal apoptosis, and blood‐brain barrier disruption, improving neurological recovery and
Ling Gao +7 more
wiley +1 more source
Adenosine Receptor Functionality and Desensitization Machinery in a Neuronal Cell Model of Angelman Syndrome. [PDF]
Contestabile M +5 more
europepmc +1 more source
Administration of opioids activates ephrinB2‐EphB1 receptor signaling. Activated EphB1 receptors induce GRK2‐mediated phosphorylation of MOR at Ser375, which initiates the internalization of MOR and reduces opioid antinociception at the behavioral level. ABSTRACT Opioids are the primary treatment for severe pain in clinical practice.
Bo Peng +7 more
wiley +1 more source
Pulsed Electromagnetic Field Exposure Attenuates Ultraviolet B-Induced Dermal Collagen Loss in Association with A2A Adenosine Receptor Signaling. [PDF]
Byun KA +6 more
europepmc +1 more source
FLUORESCENT ANTAGONISTS OF THE A3 ADENOSINE RECEPTOR
Disclosed are compounds which are fluorescently labeled antagonists of the A3 adenosine receptor. Also disclosed are diagnostic of a patient for a possible treatment by an antagonist if the A3 adenosine receptor, involving the use of one or more of these
Santosh Kumar Thatikonda +5 more
core
Diabetic bone defects remain a critical clinical challenge. A 3D‐printed BCPG‐MF@Y scaffold, embedding Yoda1‐functionalized manganese dioxide‐ferritin nanozymes, scavenges mtROS, suppresses the cGAS–STING pathway, and reverses cellular senescence, while Yoda1 activates Piezo1 to direct BMSCs fate to synergistically reprogram the osteoimmune ...
Qing‐Song Deng +16 more
wiley +1 more source
The anti-obesity effect of namodenoson, an A3 adenosine receptor agonist. [PDF]
Fishman P +5 more
europepmc +1 more source
Allosteric Modulators of the A1 Adenosine receptor
The present invention provides compounds active as allosteric modulators of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor, such as treatment of pain, in particular chronic pain
ROMAGNOLI, Romeo +2 more
core
The ROS‐responsive in situ thermosensitive MZR@SPPP hydrogel system enables dual‐stage drug loading and sustained ocular delivery. Upon administration, it gelates at ocular surface temperature, enhancing ocular adhesion. By scavenging free radicals, restoring NRF2‐mediated antioxidant defense and mitochondrial homeostasis, and suppressing inflammatory ...
Danyi Qin +13 more
wiley +1 more source
Correction: Unlocking the adenosine receptor mechanism of the tumour immune microenvironment. [PDF]
Han Y, Dong C, Hu M, Wang X, Wang G.
europepmc +1 more source

